WOBURN, Mass.--(BUSINESS WIRE)--April 4, 2006--ArQule, Inc. (Nasdaq: ARQL - News) today reported results from a Phase 1 monotherapy trial with its lead product, ARQ 501, which provided evidence of clinical tolerability and promising anti-tumor activity in cancer patients with advanced solid tumors who had failed prior treatments with chemotherapy.
